Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

Abstract

The differences in the uptake and reimbursement of two new OAB agents emphasize the impact of therapeutically novel agents on the prescription rates of older OAB agents with significant adverse effects. Further studies are needed to explain changes in the dispensing rates as more provinces list the newer drugs on their formulary.

Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study

“…There have been observed shifts in OAB treatment patterns between drugs (35,36). This is likely because newer agents have more convenient dosing regimens, therefore improving adherence (37).…”

“…1 Ki ratios; Ki represents the inhibitory constant and is defined kinetically as the ratio of rate constants for the binding of a drug to a target receptor. 2 Ki ratios determined from the antilog of pKi values ODB -Ontario drug benefits β3-adrenoceptor agonist therapy for OAB While antimuscarinic medications have been the mainstay of oral therapy for OAB, close to 30% of OAB patients are now being prescribed mirabegron (35,36), currently the only approved β3adrenoceptor agonist for OAB. These medications are particularly appealing for the OAB patient population as they appear to have limited adverse effects relative to antimuscarinics (46,47).…”

Trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada

“…We read with interest the article on trends in the use of older overactive bladder agents and uptake of fesoterodine and mirabegron in Canada . We do have some concerns however, that in certain respects the article is misleading and that the conclusions cannot be justified based upon the data presented.…”